Effects of ramiprilat-coated stents on neointimal hyperplasia, inflammation, and arterial healing in a porcine coronary restenosis model

Korean Circulation Journal

Volumn 41, Issue 9, 2011, Pages 535-541

  Hong, Young Joon ^a   Jeong, Myung Ho ^a   Song, Sun Jung ^b   Sim, Doo Sun ^a   Kim, Jung Ha ^a   Lim, Kyung Seob ^a   Hachinohe, Daisuke ^a   Ahmed, Khurshid ^a   Hwang, Seung Hwan ^a   Lee, Min Goo ^a   Ko, Jum Suk ^a   Park, Keun Ho ^a   Yoon, Hyun Ju ^a   Yoon, Nam Sik ^a   Kim, Kye Hun ^a   Park, Hyung Wook ^a   Kim, Ju Han ^a   Ahn, Youngkeun ^a   Cho, Jeong Gwan ^a   Cho, Dong Lyun ^b   Park, Jong Chun ^a   Kang, Jung Chaee ^a   more..

^a Chonnam National University Medical School   (South Korea)

^b Chonnam National University   (South Korea)

Author keywords

Angiotensin converting enzyme inhibitors; Coronary restenosis; Inflammation; Stents

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIMITOTIC AGENT; FIBRIN; RAMIPRILAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; DRUG ELUTING STENT; FEMALE; HISTOPATHOLOGY; HYPERPLASIA; INFLAMMATION; INFLAMMATORY CELL; INJURY SEVERITY; NEOINTIMA; NONHUMAN; RESTENOSIS;

EID: 80054726355     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2011.41.9.535     Document Type: Article

References (29)

1. Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol 1991;17:758-69.
2. Austin GE, Ratliff NB, Hollman J, Tabei S, Phillips DF. Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985;6:369-75. (Pubitemid 15048814)
3. Bae Y, Jeong MH, Jang YS, et al. Comparison of porcine coronary stent restenosis between MAC (Maximum Arterial Re-Creation) stent and Palmaz-Schatz stent. Korean Circ J 1998;28:89-96.
4. Giraldo AA, Esposo OM, Meis JM. Intimal hyperplasia as a cause of restenosis after percutaneous transluminal coronary angioplasty. Arch Pathol Lab Med 1985;109:173-5. (Pubitemid 15166071)
5. Ahn YK, Jeong MH, Kim JW, et al. Preventive effects of the heparin-coated stent on restenosis in the porcine model. Catheter Cardiovasc Interv 1999;48:324-30. (Pubitemid 29530070)
6. Hong YJ, Jeong MH, Lim SY, et al. Elevated preprocedural high-sensitivity C-reactive protein levels are associated with neointimal hyperplasia and restenosis development after successful coronary artery stenting. Circ J 2005;69:1477-83.
7. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. Instent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998;31:224-30. (Pubitemid 28064746)
8. Grewe PH, Deneke T, Machraoui A, Barmeyer J, Müller KM. Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen. J Am Coll Cardiol 2000;35:157-63. (Pubitemid 30061274)
9. Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999;99:44-52. (Pubitemid 29035956)
10. Pratt RE, Dzau VJ. Pharmacological strategies to prevent restenosis: lessons learned from blockade of the renin-angiotensin system. Circulation 1996;93:848-52. (Pubitemid 26074819)
11. Nakamura M, Funakoshi T, Arakawa N, Yoshida H, Makita S, Hiramori K. Effect of angiotensin-converting enzyme inhibitors on endothelium-dependent peripheral vasodilation in patients with chronic heart failure. J Am Coll Cardiol 1994;24:1321-7. (Pubitemid 24331873)
12. Hirooka Y, Imaizumi T, Masaki H, et al. Captopril improves impaired endothelium-dependent vasodilation in hypertensive patients. Hypertension 1992;20:175-80.
13. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996;94:258-65. (Pubitemid 26266107)
14. Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 1992;19:267-74.
15. Kolodgie FD, John M, Khurana C, et al. Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. Circulation 2002;106:1195-8. (Pubitemid 34988635)
16. Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999;99:44-52. (Pubitemid 29035956)
17. Finn AV, Kolodgie FD, Harnek J, et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005;112:270-8. (Pubitemid 40982311)
18. Carter AJ, Aggarwal M, Kopia GA, et al. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res 2004;63:617-24. (Pubitemid 39078675)
19. Farb A, Heller PF, Shroff S, et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 2001;104:473-9. (Pubitemid 32678280)
20. Ribichini F, Steffenino G, Dellavalle A, et al. Plasma activity and insertion/deletion polymorphism of angiotensin I-converting enzyme: a major risk factor and a marker of risk for coronary stent restenosis. Circulation 1998;97:147-54. (Pubitemid 28124671)
21. Ribichini F, Vado A, Uslenghi E, Matullo G, Piazza A. Relationship between plasma ACE activity and the proliferative healing process in coronary vessel injury after coronary stenting. Atherosclerosis 2000;152:261-3.
22. Ohishi M, Ueda M, Rakugi H, et al. Upregulation of angiotensin-converting enzyme during the healing process after injury at the site of percutaneous transluminal coronary angioplasty in humans. Circulation 1997;96:3328-37. (Pubitemid 27513402)
23. Bell L, Madri JA. Influence of the angiotensin system on endothelial and smooth muscle cell migration. Am J Pathol 1990;137:7-12. (Pubitemid 20229584)
24. Pratt RE, Dzau VJ. Pharmacological strategies to prevent restenosis: lessons learned from blockade of the renin-angiotensin system. Circulation 1996;93:848-52. (Pubitemid 26074819)
25. Campbell-Boswell M, Robertson AL Jr. Effects of angiotensin II and vasopressin on human smooth muscle cells in vitro. Exp Mol Pathol 1981;35:265-76. (Pubitemid 11011155)
26. Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991;68:450-6.
27. Scott-Burden T, Hahn AW, Resink TJ, Bühler FR. Modulation of extracellular matrix by angiotensin II: Stimulated glycoconjugate synthesis and growth in vascular smooth muscle cells. J Cardiovasc Pharmacol 1990;16(Suppl 4):S36-41. (Pubitemid 20343191)
28. Powell JS, Clozel JP, Muller RK, et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989;245:186-8. (Pubitemid 19193936)
29. Huber KC, Schwartz RS, Edwards WD, et al. Effects of angiotensin converting enzyme inhibition on neointimal proliferation in a porcine coronary injury model. Am Heart J 1993;125:695-701. (Pubitemid 23079835)